VBI Vaccines Presented Health Economics and Outcomes Research for PreHevbrio™ at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2022


CAMBRIDGE, Mass.–(BUSINESS WIRE)–VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), an immunology-focused biopharmaceutical company in pursuit of potent disease prevention and treatment, announced today that Health Economics and Outcomes Research (HEOR) comparing cost-effectiveness of Hepatitis B (HBV) vaccine to 3 company antigens, PreHevbrio™ [Hepatitis B Vaccine (Recombinant)]to a single antigen HBV vaccine, Engerix-B®, in adults in the United States was featured in a poster at the 2022 meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) which took place held from May 15 to 18, 2022.

VBI ISPOR 2022 Poster Details

Title: Cost-Effectiveness of 3-Antigen Vaccine Versus Single-Antigen Vaccine for Prevention of Hepatitis B in Adults in the United States
Conference: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Conference 2022

The full abstract and poster presentation can be viewed on the ISPOR website, here, and the poster is archived on the Posters page in the News & Resources section of the VBI website, here.

About Health Economics and Outcomes Research (HEOR)1

HEOR is the confluence of two fields that work together to provide powerful data and insights to health care decision makers: (1) health economics, which focuses on measuring and evaluating the outcomes of health care interventions health care, and (2) outcome research, which includes a set of scientific disciplines that evaluate the effect of health interventions on patients. Interest in the field of HEOR has grown exponentially as governments and other payers determine how to provide the best possible health outcomes at affordable costs.

About Hepatitis B

Hepatitis B is one of the world’s most significant infectious disease threats with more than 290 million people infected worldwide. HBV infection is the leading cause of liver disease and with current treatments it is very difficult to cure, with many patients subsequently developing liver cancer. An estimated 900,000 people die each year from complications of chronic HBV such as hepatic decompensation, cirrhosis and hepatocellular carcinoma.

About PreHevbrio™

VBI’s hepatitis B vaccine is the only 3-antigen hepatitis B vaccine, consisting of the three hepatitis B surface antigens of the hepatitis B virus – S, pre-S1 and pre-S2 . It is approved for use in the European Union/European Economic Area, USA and Israel. The brand names of this vaccine are: PreHevbri™ (EU/EEA), PreHevbrio™ (US) and Sci-B-Vac® (Israel).

Please visit www.PreHevbrio.com for important US safety information regarding PreHevbrio™ [Hepatitis B Vaccine (Recombinant)]or please see complete prescribing information in the United States.

American indication

PreHevbrio is indicated for the prevention of infections caused by all known subtypes of the hepatitis B virus. PreHevbrio is approved for use in adults 18 years of age and older.

Important US Safety Information (ISI)

Do not give PreHevbrio to people who have had a history of severe allergic reaction (eg, anaphylaxis) after a previous dose of any hepatitis B vaccine or any component of PreHevbrio.

Appropriate medical treatment and supervision should be available to manage possible anaphylactic reactions following administration of PreHevbrio.

Immunocompromised people, including those on immunosuppressive therapy, may have a decreased immune response to PreHevbrio.

PreHevbrio may not prevent hepatitis B infection, which has a long incubation period, in people who have unrecognized hepatitis B infection when the vaccine is given.

The most common adverse reactions (>10%) in adults 18-44 years old, adults 45-64 years old, and adults 65 years and older were pain and tenderness at the injection site, myalgia, fatigue and headaches.

There is a Pregnancy Exposure Registry that monitors pregnancy outcomes in women who received PreHevbrio during pregnancy. Women receiving PreHevbrio during pregnancy are encouraged to contact 1-888-421-8808 (toll-free).

To report SUSPECTED ADVERSE REACTIONS, contact VBI Vaccines at 1-888-421-8808 (toll-free) or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

Please see complete prescribing information.

About VBI Vaccines Inc.

VBI Vaccines Inc. (“VBI”) is an immunology-focused biopharmaceutical company in the pursuit of potent disease prevention and treatment. Through its innovative Virus-Like Particle (“VLP”) approach, including proprietary enveloped VLP (“eVLP”) platform technology, VBI is developing candidate vaccines that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. system. VBI is committed to targeting and defeating important infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers, including glioblastoma (GBM). VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel. For more information, visit www.vbivaccines.com.


  1. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) forward-looking information cautionary statement. About the HEOR. https://www.ispor.org/heor-resources/about-heor.

Caution regarding forward-looking information

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian law. securities laws (collectively, “forward-looking statements”). The Company cautions that these statements involve risks and uncertainties that may materially affect the results of the Company’s operations. These forward-looking statements are based on management’s beliefs as well as assumptions made by management and information currently available to it. Actual results could differ materially from those contemplated by the forward-looking statements due to certain factors, including, but not limited to, the impact of general economic, industrial or political conditions in the United States or internationally. ; the impact of the ongoing COVID-19 pandemic on our clinical studies, manufacturing, business plan and the global economy; the ability to successfully manufacture and commercialize PreHevbrio/PreHevbri; the ability to establish that potential products are effective or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of candidate pipelines and the commercialization of PreHevbrio/PreHevbri; the ability to obtain appropriate or necessary regulatory approvals to commercialize potential products; the ability to obtain future financing for development products and working capital and to obtain such financing on commercially reasonable terms; the Company’s ability to manufacture product candidates on a commercial scale or in collaboration with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to obtain and enforce legal rights related to the Company’s products. A discussion of these and other factors, including risks and uncertainties relating to the Company, is set forth in the Company’s filings with the SEC and Canadian securities regulators, including its Annual Report on Form 10. -K filed with the SEC on March 7, 2022, and filed with Canadian security authorities at sedar.com on March 7, 2022, as may be supplemented or amended by the Company’s Quarterly Reports on Form 10- Q. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on these forward-looking statements, which are qualified in their entirety by this cautionary statement. All such forward-looking statements made herein are based on our current expectations and we undertake no obligation or duty to update or revise any forward-looking statements for any reason, except as required by law.


About Author

Comments are closed.